March 31st 2023
Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.
Community Practice Connections™: 2nd Annual Optometry Times™ EyeCon
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(CME Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(COPE Credit) Expert Illustrations & Commentaries™: Envisioning New Therapies for Meibomian Gland Dysfunction-Associated DED
View More
(COPE Credit) Community Practice Connections™: Expert Approaches in Cataract Surgery – Managing Advances in Techniques and Technologies With an Updated Armamentarium
View More
3-week therapeutics for MGD equivalent to 6-week treatment in efficacy and adverse events
March 27th 2023Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.
Refractive Error Among CHildren (REACH): A Lens on the Future
March 23rd 2023REACH operates with three objectives: 1) eliminate barriers to eye health for school children; 2) improve the quality of school eye health services; and 3) create a positive, sustainable environment at schools where eye health services are provided, ensuring children feel comfortable to access these services.